These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 36642846)

  • 1. Deep Eutectic Solvents for Subcutaneous Delivery of Protein Therapeutics.
    Curreri AM; Kim J; Dunne M; Angsantikul P; Goetz M; Gao Y; Mitragotri S
    Adv Sci (Weinh); 2023 Mar; 10(7):e2205389. PubMed ID: 36642846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting bioavailability of monoclonal antibodies after subcutaneous administration: Open innovation challenge.
    Sánchez-Félix M; Burke M; Chen HH; Patterson C; Mittal S
    Adv Drug Deliv Rev; 2020 Dec; 167():66-77. PubMed ID: 32473188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subcutaneous delivery of monoclonal antibodies: How do we get there?
    Viola M; Sequeira J; Seiça R; Veiga F; Serra J; Santos AC; Ribeiro AJ
    J Control Release; 2018 Sep; 286():301-314. PubMed ID: 30077735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms Influencing the Pharmacokinetics and Disposition of Monoclonal Antibodies and Peptides.
    Datta-Mannan A
    Drug Metab Dispos; 2019 Oct; 47(10):1100-1110. PubMed ID: 31043438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities.
    Bittner B; Richter W; Schmidt J
    BioDrugs; 2018 Oct; 32(5):425-440. PubMed ID: 30043229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of physiochemical properties on the subcutaneous absorption and bioavailability of monoclonal antibodies.
    Datta-Mannan A; Estwick S; Zhou C; Choi H; Douglass NE; Witcher DR; Lu J; Beidler C; Millican R
    MAbs; 2020 Jan; 12(1):1770028. PubMed ID: 32486889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent Developments on Ionic Liquids and Deep Eutectic Solvents for Drug Delivery Applications.
    Qader IB; Prasad K
    Pharm Res; 2022 Oct; 39(10):2367-2377. PubMed ID: 35739370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variability of insulin absorption and insulin action.
    Heinemann L
    Diabetes Technol Ther; 2002; 4(5):673-82. PubMed ID: 12450450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting the clinical subcutaneous absorption rate constant of monoclonal antibodies using only the primary sequence: a machine learning approach.
    Bei R; Thomas J; Kapur S; Woldeyes M; Rauk A; Robarge J; Feng J; Abbou Oucherif K
    MAbs; 2024; 16(1):2352887. PubMed ID: 38745390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The absorption of subcutaneously injected short-acting soluble insulin: influence of injection technique and concentration.
    Hildebrandt P; Sestoft L; Nielsen SL
    Diabetes Care; 1983; 6(5):459-62. PubMed ID: 6400706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simple Approach to Accurately Predict Pharmacokinetics of Therapeutic Monoclonal Antibodies after Subcutaneous Injection in Humans.
    Haraya K; Tachibana T
    Clin Pharmacokinet; 2021 Jan; 60(1):111-120. PubMed ID: 32779124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subcutaneous delivery of biotherapeutics: challenges at the injection site.
    Sequeira JAD; Santos AC; Serra J; Estevens C; Seiça R; Veiga F; Ribeiro AJ
    Expert Opin Drug Deliv; 2019 Feb; 16(2):143-151. PubMed ID: 30632401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accelerating and improving the consistency of rapid-acting analog insulin absorption and action for both subcutaneous injection and continuous subcutaneous infusion using recombinant human hyaluronidase.
    Muchmore DB; Vaughn DE
    J Diabetes Sci Technol; 2012 Jul; 6(4):764-72. PubMed ID: 22920800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal antibody and protein therapeutic formulations for subcutaneous delivery: high-concentration, low-volume vs. low-concentration, high-volume.
    Desai M; Kundu A; Hageman M; Lou H; Boisvert D
    MAbs; 2023; 15(1):2285277. PubMed ID: 38013454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pressurized Natural Deep Eutectic Solvent Extraction of Galanthamine and Related Alkaloids from Narcissus pseudonarcissus.
    Rachmaniah O; Wilson EG; Choi YH; Witkamp GJ; Verpoorte R
    Planta Med; 2022 Aug; 88(9-10):814-825. PubMed ID: 35304734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unchanged insulin absorption after 4 days' use of subcutaneous indwelling catheters for insulin injections.
    Hanas SR; Carlsson S; Frid A; Ludvigsson J
    Diabetes Care; 1997 Apr; 20(4):487-90. PubMed ID: 9096966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ionic liquids and deep eutectic solvents for the stabilization of biopharmaceuticals: A review.
    Veríssimo NVP; Mussagy CU; Bento HBS; Pereira JFB; Santos-Ebinuma VC
    Biotechnol Adv; 2024; 71():108316. PubMed ID: 38199490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, biocompatibility and bioavailability of a controlled release monoclonal antibody formulation.
    Schweizer D; Vostiar I; Heier A; Serno T; Schoenhammer K; Jahn M; Jones S; Piequet A; Beerli C; Gram H; Goepferich A
    J Control Release; 2013 Dec; 172(3):975-82. PubMed ID: 24140353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anatomical, physiological, and experimental factors affecting the bioavailability of sc-administered large biotherapeutics.
    Fathallah AM; Balu-Iyer SV
    J Pharm Sci; 2015 Feb; 104(2):301-6. PubMed ID: 25411114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiphysics Simulation of Local Transport and Absorption Coupled with Pharmacokinetic Modeling of Systemic Exposure of Subcutaneously Injected Drug Solution.
    Corpstein CD; Hou P; Park K; Li T
    Pharm Res; 2023 Dec; 40(12):2873-2886. PubMed ID: 37344601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.